MDS Considers Strategic Alternatives
Apparently, MDS has agreed to Obrem’s request for an evaluation of alternatives. Obrem and affiliates hold 13.0% of MDS stock. In November 2008, Obrem agreed not to engage in proxy actions until after MDS’s annual meeting in March.
Toronto, Canada 2/2/09; New York NY 10/30/08—MDS announced that is has formed a committee of independent directors to support its review of alternatives for improving shareholder value. MDS has hired Goldman, Sachs & Co. and RBC Capital Markets as financial advisors. In an October 2008 press release, Obrem Capital Markets disclosed its discussions with MDS regarding actions to increase shareholder value, including a sale of the assets of MDS Analytical Technologies.

